Thrombolysis for acute deep vein thrombosis

Area of Science:

• Vascular Medicine
• Interventional Cardiology
• Thrombosis Research

Background:

• Standard deep vein thrombosis (DVT) management focuses on immediate complication reduction.
• Thrombolysis, or clot-dissolving drugs, may mitigate long-term post-thrombotic syndrome (PTS) complications like pain, swelling, and skin changes.
• This review is an update of research first published in 2004.

Purpose of the Study:

• To evaluate thrombolytic therapy combined with anticoagulation versus anticoagulation alone for acute lower limb deep vein thrombosis (DVT).
• To assess impacts on pulmonary embolism, recurrent venous thromboembolism, major bleeding, and post-thrombotic complications.
• To determine effects on venous patency and function.

Main Methods:

• A systematic review and meta-analysis of randomized controlled trials (RCTs) comparing thrombolysis plus anticoagulation with anticoagulation alone for acute DVT.
• Searches conducted in the Cochrane Peripheral Vascular Diseases Group Specialised Register and CENTRAL up to April 2013.
• Risk of bias assessment and data extraction performed independently by multiple reviewers.

Main Results:

• Thrombolysis significantly increased complete clot lysis and venous patency in early and intermediate follow-ups.
• A significant reduction in post-thrombotic syndrome (PTS) incidence was observed with thrombolysis (RR 0.64).
• Thrombolysis was associated with a significant increase in bleeding complications (RR 2.23), with three strokes reported in older trials.

Conclusions:

• Thrombolysis enhances venous patency and reduces PTS by one-third after proximal DVT.
• Strict eligibility criteria are crucial to minimize bleeding risks, thus limiting treatment applicability.
• Catheter-directed thrombolysis (CDT) is increasingly studied and shows similar results to systemic administration.